

**In the Claims**

Please replace all prior versions, and listings, of claims in the application with the following list of claims.

1.-9. (Canceled)

10. (Currently amended) A method Method for identifying a compound that can be used in the prevention and/or treatment of a metabolic disease modulator of a protein or polypeptide of claim 8, for example from a set or library of test chemicals, said method at least comprising the steps of:

contacting a protein or polypeptide comprising one of the amino acid sequences of SEQ ID NOs: 1, 6 and/or 8, or an analog, variant, allele, ortholog, part and/or fragment thereof that has at least 50% amino acid sequence identity with one or more of the amino acid sequences of SEQ ID NOs: 1, 6 and/or 8 and that has alcohol dehydrogenase activity of claim 8 with said a test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said protein or polypeptide; and optionally

detecting the signal that may thus be generated, said signal identifying a compound that can be used in the prevention and/or treatment of the metabolic disease modulator of said protein or polypeptide.

11.-18. (Canceled)

19. (Previously presented) Method for identifying a modulator of a protein or polypeptide, for example from a set or library of test chemicals, said method at least comprising the steps of:

contacting a host cell or host organism of claim 5 with said test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said expressed and/or produced protein or polypeptide; and optionally

detecting the signal that may thus be generated, said signal identifying a modulator of said protein or polypeptide.

20. (New) The method according to claim 10, wherein the metabolic disease is selected from hyperglycemic conditions, Type I and Type II diabetes, severe insulin resistance, hyperinsulinemia, hyperlipidemia, obesity, insulin-resistant diabetes, Mendenhall's Syndrome, Werner Syndrome, leprechaunism, lipoatrophic diabetes, and other lipoatrophies, hypertension, osteoporosis and/or lipodystrophy, metabolic syndrome and dyslipidemia.
21. (New) The method according to claim 20 wherein the metabolic disease is diabetes.
22. (New) The method according to claim 20 wherein the metabolic disease is obesity.
23. (New) The method according to claim 10 wherein the compound is an inhibitor of the protein or polypeptide.
24. (New) The method according to claim 10 wherein the test chemical is a small molecule.